Neurimmune is a clinical-stage biopharmaceutical company building next generation antibody therapeutics. The company pioneers amyloid depletion as a novel therapeutic mechanism to treat CNS and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy.

Emerging Therapies

View all
Cardiac amyloid targeted for immune-mediated clearance

Pioneering Amyloid Depletion

Protein aggregation diseases - such as Alzheimer’s, Parkinson’s, ALS, and amyloid cardiomyopathies - are caused by the misfolding and aggregation of endogenous proteins in tissues like the brain or heart. These misfolded proteins lose normal function, resist degradation, and often become toxic, leading to progressive organ damage. Neurimmune is pioneering a new class of transformative therapeutics that precisely recognize, target, and eliminate aggregated proteins across multiple tissues, addressing the root cause of these devastating diseases.

Amyloid Depletion

Scientific Publications